Safety of Tepotinib in Patients with MET Exon 14 Skipping NSCLC and Recommendations for Management - Clinical Lung Cancer
JCM | Free Full-Text | The Role of MET Inhibitor Therapies in the Treatment of Advanced Non-Small Cell Lung Cancer | HTML
Biomedicines | Free Full-Text | Recent Progress and Advances in HGF/MET-Targeted Therapeutic Agents for Cancer Treatment | HTML
Novartis Reports Results of Capmatinib in P-II GEOMETRY mono-1 Study for Non-Small Cell
A Phase 2 Study of Capmatinib in Patients With MET-Altered Lung Cancer Previously Treated With a MET Inhibitor - Journal of Thoracic Oncology
MET Inhibitors Active in Advanced NSCLC | MedPage Today
Real-world insights into patients with advanced NSCLC and MET alterations - Lung Cancer
Oncogenic switch and single-agent MET inhibitor sensitivity in a subset of EGFR-mutant lung cancer
FDA approves Tabrecta for treatment of metastatic NSCLC
MET Exon 14 Skipping Alterations in NSCLC: Current Understanding and Therapeutic Advances - touchONCOLOGY
Novartis bags FDA priority review in tight lung cancer race against Merck KGaA | Fierce Pharma
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study - The Lancet Oncology
Novartis announces MET inhibitor Tabrecta™ approved in Japan for advanced non-small cell lung cancer with METex14 | Novartis
Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration | Nature Medicine
FDA approved ALK inhibitors with substantial impact in the field of... | Download Scientific Diagram
Safety and Tolerability of c-MET Inhibitors in Cancer | SpringerLink
The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping - ScienceDirect
Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies - Cancer Treatment Reviews
Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In Vitro - Journal of Thoracic Oncology
Molecular correlates of response to capmatinib in advanced non-small-cell lung cancer: clinical and biomarker results from a phase I trial - Annals of Oncology
Schematic representation of MET signaling blockade by capmatinib.... | Download Scientific Diagram
MET-dependent solid tumours — molecular diagnosis and targeted therapy | Nature Reviews Clinical Oncology
Novartis pulls ahead of Merck in MET-positive lung cancer race - PMLiVE
Novartis promising anti-tumor combination therapy - K-Recruiting
The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping - ScienceDirect
Has PD-1 MET Its Match in Hepatocellular Carcinoma? - Gastroenterology
